메뉴 건너뛰기




Volumn 100, Issue 12, 2011, Pages 5174-5184

Biopharmaceutical characterization of ciprofloxacin HCl-ferrous sulfate interaction

Author keywords

Bioavailability; Biopharmaceutics Classification System (BCS); Ciprofloxacin HCl; Dissolution; Drug interaction; Ferrous sulfate; In silico modeling; Oral absorption; Solubility

Indexed keywords

CIPROFLOXACIN; FERROUS SULFATE; WATER;

EID: 80054921557     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22707     Document Type: Article
Times cited : (21)

References (46)
  • 1
    • 0028948839 scopus 로고
    • A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability
    • Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
    • (1995) Pharm Res , vol.12 , pp. 413-420
    • Amidon, G.L.1    Lennernas, H.2    Shah, V.P.3    Crison, J.R.4
  • 2
    • 65549101635 scopus 로고    scopus 로고
    • The Science of USP 1 and 2 dissolution: Present challenges and future relevance
    • Gray V, Kelly G, Xia M, Butler C, Thomas S, Mayock S. 2009. The Science of USP 1 and 2 dissolution: Present challenges and future relevance. Pharm Res 26:1289-1302.
    • (2009) Pharm Res , vol.26 , pp. 1289-1302
    • Gray, V.1    Kelly, G.2    Xia, M.3    Butler, C.4    Thomas, S.5    Mayock, S.6
  • 3
    • 77955947927 scopus 로고    scopus 로고
    • The use of biorelevant dissolution media to forecast the in vivo performance of a drug
    • Klein S. 2010. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J 12:397-406.
    • (2010) AAPS J , vol.12 , pp. 397-406
    • Klein, S.1
  • 4
    • 85030489424 scopus 로고    scopus 로고
    • US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidances for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System.
    • US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2000. Guidances for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System.
    • (2000)
  • 5
    • 80054946642 scopus 로고    scopus 로고
    • European Medicines Agency (EMA). Committee for proprietary medicinal products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence.
    • European Medicines Agency (EMA). 2010. Committee for proprietary medicinal products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence.
    • (2010)
  • 6
    • 77955248335 scopus 로고    scopus 로고
    • The biowaiver extension for BCS class III drugs: The effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation
    • Tsume Y, Amidon GL. 2010. The biowaiver extension for BCS class III drugs: The effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. Mol Pharm 7:1235-1243.
    • (2010) Mol Pharm , vol.7 , pp. 1235-1243
    • Tsume, Y.1    Amidon, G.L.2
  • 7
    • 0032927254 scopus 로고    scopus 로고
    • Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications
    • Fleisher D, Li C, Zhou Y, Pao LH, Karim A. 1999. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 36:233-254.
    • (1999) Clin Pharmacokinet , vol.36 , pp. 233-254
    • Fleisher, D.1    Li, C.2    Zhou, Y.3    Pao, L.H.4    Karim, A.5
  • 8
    • 65549103408 scopus 로고    scopus 로고
    • Predicting pharmacokinetics of drugs using physiologically based modeling-Application to food effects
    • Parrott N, Lukacova V, Fraczkiewicz G, Bolger MB. 2009. Predicting pharmacokinetics of drugs using physiologically based modeling-Application to food effects. AAPS J 11:45-53.
    • (2009) AAPS J , vol.11 , pp. 45-53
    • Parrott, N.1    Lukacova, V.2    Fraczkiewicz, G.3    Bolger, M.B.4
  • 9
    • 28444451169 scopus 로고    scopus 로고
    • A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study
    • Kuentz M, Nick S, Parrott N, Röthlisberger D. 2006. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci 27:91-99.
    • (2006) Eur J Pharm Sci , vol.27 , pp. 91-99
    • Kuentz, M.1    Nick, S.2    Parrott, N.3    Röthlisberger, D.4
  • 10
    • 43349105478 scopus 로고    scopus 로고
    • Rationale for ibuprofen co-administration with antacids: Potential interaction mechanisms affecting drug absorption
    • Parojčić J, Corrigan OI. 2008. Rationale for ibuprofen co-administration with antacids: Potential interaction mechanisms affecting drug absorption. Eur J Pharm Biopharm 69:640-647.
    • (2008) Eur J Pharm Biopharm , vol.69 , pp. 640-647
    • Parojčić, J.1    Corrigan, O.I.2
  • 11
    • 0024447995 scopus 로고
    • Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers
    • Polk RE, Healy DP, Sahai J, Drwal L, Racht E. 1989. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 33:1841-1844.
    • (1989) Antimicrob Agents Chemother , vol.33 , pp. 1841-1844
    • Polk, R.E.1    Healy, D.P.2    Sahai, J.3    Drwal, L.4    Racht, E.5
  • 12
    • 0025054283 scopus 로고
    • Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate
    • Brouwers JR, Van der Kam HJ, Sijtsma J, Proost JH. 1990. Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate. Pharm Weekbl Sci 12:182-183.
    • (1990) Pharm Weekbl Sci , vol.12 , pp. 182-183
    • Brouwers, J.R.1    Van der Kam, H.J.2    Sijtsma, J.3    Proost, J.H.4
  • 13
    • 0025978806 scopus 로고
    • Clinical and chemical interactions between iron preparations and ciprofloxacin
    • Campbell
    • Kara M, Hasinoff BB, McKay WD, Campbell 1991. Clinical and chemical interactions between iron preparations and ciprofloxacin. Br J Clin Pharmacol 31:257-261.
    • (1991) Br J Clin Pharmacol , vol.31 , pp. 257-261
    • Kara, M.1    Hasinoff, B.B.2    McKay, W.D.3
  • 14
    • 0028235252 scopus 로고
    • The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin
    • Lehto P, Kivisto TK, Neuvonen JP. 1994. The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. Br J Clin Pharmacol 37:82-85.
    • (1994) Br J Clin Pharmacol , vol.37 , pp. 82-85
    • Lehto, P.1    Kivisto, T.K.2    Neuvonen, J.P.3
  • 16
    • 0025972964 scopus 로고
    • Iron supplements: A common cause of drug interactions
    • Campbell RCN, Hasinoff BB. 1991. Iron supplements: A common cause of drug interactions. Br J Clin Pharmacol 31:251-255.
    • (1991) Br J Clin Pharmacol , vol.31 , pp. 251-255
    • Campbell, R.C.N.1    Hasinoff, B.B.2
  • 17
    • 0030010835 scopus 로고    scopus 로고
    • Pharmacokinetics of ciprofloxacin metal complexes
    • Kozjek F, Palka E, Krizman I, Vodopivec P. 1996. Pharmacokinetics of ciprofloxacin metal complexes. Acta Pharm 46:109-114.
    • (1996) Acta Pharm , vol.46 , pp. 109-114
    • Kozjek, F.1    Palka, E.2    Krizman, I.3    Vodopivec, P.4
  • 18
    • 0028344283 scopus 로고
    • A physico-chemical study of the interaction of ciprofloxacin and ofloxacin with polyvalent cations
    • Sanchez BM, Cabarga MM, Navarro AS, Hurle AD. 1994. A physico-chemical study of the interaction of ciprofloxacin and ofloxacin with polyvalent cations. Int J Pharm 106:229-235.
    • (1994) Int J Pharm , vol.106 , pp. 229-235
    • Sanchez, B.M.1    Cabarga, M.M.2    Navarro, A.S.3    Hurle, A.D.4
  • 20
    • 77954860340 scopus 로고    scopus 로고
    • Metal cation-fluoroquinolone complexes do not permeate through the intestinal absorption barrier
    • Žakelj S, Berginc K, Ursic D, Veber M, Kristl A. 2010. Metal cation-fluoroquinolone complexes do not permeate through the intestinal absorption barrier. J Pharm Biomed Anal 53:655-659.
    • (2010) J Pharm Biomed Anal , vol.53 , pp. 655-659
    • Žakelj, S.1    Berginc, K.2    Ursic, D.3    Veber, M.4    Kristl, A.5
  • 21
    • 28444462195 scopus 로고    scopus 로고
    • Interactions between ciprofloxacin and antacids-dissolution and adsorption studies
    • Arayne MS, Sultana N, Hussain F. 2005. Interactions between ciprofloxacin and antacids-dissolution and adsorption studies. Drug Metabol Drug Interact 21(2):117-129.
    • (2005) Drug Metabol Drug Interact , vol.21 , Issue.2 , pp. 117-129
    • Arayne, M.S.1    Sultana, N.2    Hussain, F.3
  • 22
    • 34247142812 scopus 로고    scopus 로고
    • Influence of metal cations on the solubility of fluoroquinolones
    • Žakelj S, Berginc K, Ursic D, Kristl A. 2007. Influence of metal cations on the solubility of fluoroquinolones. Pharmazie 62:318-320.
    • (2007) Pharmazie , vol.62 , pp. 318-320
    • Žakelj, S.1    Berginc, K.2    Ursic, D.3    Kristl, A.4
  • 23
    • 0036783919 scopus 로고    scopus 로고
    • The interactions of metal ions with quinolone antibacterial agents
    • Turel I. 2002. The interactions of metal ions with quinolone antibacterial agents. Coord Chem Rev 232:22-47.
    • (2002) Coord Chem Rev , vol.232 , pp. 22-47
    • Turel, I.1
  • 24
    • 67649336602 scopus 로고    scopus 로고
    • Analysis of the factors that significantly influence the stability of fluoroquinolone-metal complexes
    • Urbaniak B, Kokot Z. 2009. Analysis of the factors that significantly influence the stability of fluoroquinolone-metal complexes. Anal Chim Acta 647:54-59.
    • (2009) Anal Chim Acta , vol.647 , pp. 54-59
    • Urbaniak, B.1    Kokot, Z.2
  • 25
    • 40949123409 scopus 로고    scopus 로고
    • Iron (III) complexes: Preparation, characterization, antibacterial activity and DNA-binding
    • Pansuriya PB, Patel MN. 2008. Iron (III) complexes: Preparation, characterization, antibacterial activity and DNA-binding. J Enzyme Inhib Med Chem 23:230-239.
    • (2008) J Enzyme Inhib Med Chem , vol.23 , pp. 230-239
    • Pansuriya, P.B.1    Patel, M.N.2
  • 26
    • 0037454602 scopus 로고    scopus 로고
    • Iron (II) and iron (III) perchlorate complexes of ciprofloxacin and norfloxacin
    • Al-Mustafa J, Tashtoush B. 2003. Iron (II) and iron (III) perchlorate complexes of ciprofloxacin and norfloxacin. J Coord Chem 56:113-124.
    • (2003) J Coord Chem , vol.56 , pp. 113-124
    • Al-Mustafa, J.1    Tashtoush, B.2
  • 28
    • 0023794347 scopus 로고
    • Pharmacokinetics of intravenous ciprofloxacin at three different doses
    • Ljungberg B, Nilsson-Ehle I. 1988. Pharmacokinetics of intravenous ciprofloxacin at three different doses. J Antimicrob Chemother 22:715-720.
    • (1988) J Antimicrob Chemother , vol.22 , pp. 715-720
    • Ljungberg, B.1    Nilsson-Ehle, I.2
  • 29
    • 0035478779 scopus 로고    scopus 로고
    • Predicting the impact of physiological and biochemical processes on oral drug bioavailability
    • Agoram B, Woltosz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50:41-67.
    • (2001) Adv Drug Deliv Rev , vol.50 , pp. 41-67
    • Agoram, B.1    Woltosz, W.S.2    Bolger, M.B.3
  • 31
    • 80054956785 scopus 로고    scopus 로고
    • pION INC. Molecule of the month-ciprofloxacin HCl.
    • pION INC. 2003. Molecule of the month-ciprofloxacin HCl.
    • (2003)
  • 32
    • 0025300849 scopus 로고
    • Extravascular penetration of ciprofloxacin
    • Bergan T. 1990. Extravascular penetration of ciprofloxacin. Diagn Microbiol Infect Dis 13:103-104.
    • (1990) Diagn Microbiol Infect Dis , vol.13 , pp. 103-104
    • Bergan, T.1
  • 33
    • 0004144140 scopus 로고    scopus 로고
    • Martindale. 34th edition. London, UK: Royal Pharmaceutical Society.
    • Martindale. 2004. The Extra Pharmacopoeia. 34th edition. London, UK: Royal Pharmaceutical Society.
    • (2004) The Extra Pharmacopoeia
  • 40
    • 0025309060 scopus 로고
    • Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with hf-capsule
    • Harder S, Fuhr U, Beermann D, Staib AH. 1990. Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with hf-capsule. Br J Clin Pharmacol 30:35-39.
    • (1990) Br J Clin Pharmacol , vol.30 , pp. 35-39
    • Harder, S.1    Fuhr, U.2    Beermann, D.3    Staib, A.H.4
  • 43
    • 68249133855 scopus 로고    scopus 로고
    • Role of physiological intestinal water in oral absorption
    • Sutton CS. 2009. Role of physiological intestinal water in oral absorption. AAPS J 11:277-285.
    • (2009) AAPS J , vol.11 , pp. 277-285
    • Sutton, C.S.1
  • 45
    • 77957016539 scopus 로고    scopus 로고
    • Adsorption and intercalation of ciprofloxacin on montmorillonite
    • Wu Q, Li Z, Hong H, Yin K, Tie L. 2010. Adsorption and intercalation of ciprofloxacin on montmorillonite. Appl Clay Sci 50:204-211.
    • (2010) Appl Clay Sci , vol.50 , pp. 204-211
    • Wu, Q.1    Li, Z.2    Hong, H.3    Yin, K.4    Tie, L.5
  • 46
    • 0028578066 scopus 로고
    • Synthesis, characterization and crystal structure of copper(II) complex with quinolone family member (Ciprofloxacin): Bis(1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazin-1ylquinoline-3-carboxylate)copper(II) chloride hexahydrate
    • Turel I, Leban I, Bukovec N. 1994. Synthesis, characterization and crystal structure of copper(II) complex with quinolone family member (Ciprofloxacin): Bis(1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-piperazin-1ylquinoline-3-carboxylate)copper(II) chloride hexahydrate. J Inorg Biochem 56:273-282.
    • (1994) J Inorg Biochem , vol.56 , pp. 273-282
    • Turel, I.1    Leban, I.2    Bukovec, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.